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A simple risk score for prediction of cardiac rupture in patients with
ST-elevation myocardial infarction
Geng Qian, Yundai Chen, Feng Cao, Zhenhong Fu
Department of Cardiology, Chinese People’s Liberation Army
General Hospital
OBJECTIVES Cardiac rupture is a potentially fatal mechanical
complication of ST-elevation myocardial infarction (STEMI). The aim
of this study was to develop and validate a practical risk score to
predict the cardiac rupture after the STEMI.
METHODS A total of 11234 consecutive STEMI patients from 6 centers
in China were studied in our trial, we ﬁrstly developed a simpliﬁed
fast-track risk model from 7455 STEMI patients, and then prospec-
tively validated the score system using receiver-operating character-
istic (ROC) curves with data from 3779 STEMI patients.
RESULTS The incidence of cardiac rupture was 2.14% (240/11234), but
the thirty-day mortality was up to 89.6%. We developed a risk model
which had 7 independent baseline predictors (female sex, advanced
age, anterior myocardial infarction, delayed admission, elevated
white blood cell count, anemia, model c-statistic¼0.74). The cardiac
rupture risk score differentiated patients with thirty-day rate of car-
diac rupture ranging from 0.3% to over 10%. The risk score system
demonstrated a good risk predictive value with a c-statistic of 0.78
(95% CI 0.73–0.84) in validation set based on ROC analysis. Beta-
blockers could lower the risk of cardiac rupture for the STEMI patients
with high risk (14.4% vs. 18.6%, p<0.001). Intra-aortic balloon pump
(IABP) is also associated with the decreased incidence of cardiac
rupture for the STEMI patients with high risk (12.4% vs. 16.8%,
p<0.001).
CONCLUSIONS A simple risk score system based on 7 baseline clinical
variables could identiﬁes patients at increased risk for CR, for whom
appropriate treatment strategies can be implemented.
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Expression characteristics of neutrophil and mononuclear-phagocyte
related genes in the SAP and AMI stages of coronary artery disease.
Chuanrong Li, Lemin Wang
Department of Cardiology, Tongji Hospital, Tongji University School of
Medicine, Shanghai, China
OBJECTIVES To investigate expression differences of neutrophil and
mononuclear phagocyte related genes mRNA among acute myocardial
infarction (AMI), stable angina pectoris (SAP) and control groups, and
then discuss their expression characteristics in the SAP and AMI
stages of coronary artery disease.
METHODS Whole Human Genome Oligo Microarrays were applied to
assess the differential expres-sion characteristics of neutrophil and
mononuclear phagocyte related mRNAs in patients with AMI (n¼20),
SAP (n¼20) and controls (n¼20).
RESULTS (1) Almost all colony-stimulating factors (CSF) and their
receptors related mRNAs was up-regulated in AMI and SAP groups
compared with the control group, and the expression of GM-CSFR and
G-CSFR mRNAs in the AMI group was signiﬁcantly up-regu-
lated(P<0.01) than the SAP and control groups (2) The expression of
mRNAs related to monocyte chemoattractant protein-1(MCP-1), CCR2
(MCP-1 receptor) and CXCR2(IL-8 receptor) was signiﬁcantly up-
regulated (P<0.01) in AMI group compared with SAP and control
groups, and IL-8 mRNA expression in the AMI group was clearly
higher (P<0.05) than the controls. (3) All mRNAs expression related to
opsonic receptors(IgG FcR and C3bR/C4bR) was signiﬁcantly up-
regulated (P<0.01) in AMI group compared with SAP and control
group, and the SAP group showed an upward trend compared with the
controls. (4) Most pattern recognition receptor (PRR)-related mRNAs
expression was up-regulated in AMI group compared with SAP and
control groups. Most Toll like receptor (TLR) mRNAs expression was
signiﬁcantly up-regulated (P<0.01) than the SAP and control groups;
macrophage scavenger receptor (MSR) mRNA was signiﬁcantly
up-regulated (P<0.01) in AMI group compared with the control group,
and the SAP group showed an upward trend compared with the
controls.
CONCLUSIONS The expression of most neutrophil and mono-
nuclear-macrophage function related genes mRNAs was signiﬁ-cantly up-regulated by stages during the progression of CAD,
suggesting that the adhesive, chemotactic and phagocytic func-
tions of neutrophil and mononuclear-macrophage are strengthened
in the occurrence and development of coronary atherosclerosis
and AMI and show an stepped upward trend as the disease pro-
gresses.
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Prognostic Value of Plasma Intermedin Level in Patients with
Non-ST-Segment Elevation Acute Coronary Syndrome
Pengyang Li,1 Bin Wang1,2
1Peking University Aerospace School of Clinical Medicine, Peking
University Health Science Center; 2Department of Cardiology,
Aerospace Central Hospital
OBJECTIVES Intermedin (IMD), an autocrine/paracrine biological
active peptide, plays a critical role in maintaining vascular homeo-
stasis and is widely involved in the pathogenesis of cardiovascular
disease. Recent study has shown high plasma IMD level associated
with poor outcomes for patients with ST-segment elevation acute
myocardial infarction and adds prognostic value to the Global Registry
of Acute Coronary Events score (GRACE score). However, the prog-
nostic role of IMD level in non-ST-segment elevation acute coronary
syndrome (NSTE-ACS) remains unknown. We aimed to assess the
prognostic performance of IMD level in a prospective cohort of pa-
tients with NSTE-ACS.
METHODS Plasma IMD was determined by radioimmunoassay in 132
NSTE-ACS patients on admission to hospital. The endpoint was
major adverse cardiovascular events (MACEs), including death,
heart failure, hospitalization, and acute myocardial infarction, over
follow-up.
RESULTS In total, 22 patients exhibited MACEs during follow-up
(mean 9564 days, range 2 to 249 days). Median IMD level was
higher for patients with MACEs than MACE-free survivors (390.3
[range 127.2 to 1772.2] vs. 308.9 [range 73.0 to 2121.9] pg/ml,
p<0.001). The area under the receiver-operating characteristic curve
for IMD and N-terminal pro-B-type brain natriuretic peptide (NT-
proBNP) did not signiﬁcantly differ (0.75 and 0.78, both p<0.001,
respectively; p¼0.792). On Cox regression analysis with cardiovas-
cular risk variables and NT-proBNP, the risk of MACEs increased
3.89-fold (95% conﬁdence interval 1.46–10.33; p¼0.006) with high
IMD level (upper tertile [>362.4] vs. lower 2 tertiles [362.4]
pg/ml).
CONCLUSIONS IMD might be a promising prognostic biomarker for
predicting MACEs in patients with NSTE-ACS.GW26-e1599
The use of statins maybe is safety in acute coronary syndrome patients
with hepatitis B Virus
Zhenjun Wang, Jieyun Liu, Wen Yang, Chenchen Li, Yaoxin Wang,
Lei Qin
The Kaifeng central Hospital
OBJECTIVES To investigate the safety of HMGCoA reductase inhibitor
(statins) use in acute coronary syndrome (ACS) patients with hepatitis
B Virus.
METHODS 108 ACS patients with hepatitis B Virus and normal liver
function aged 45-70 years provided the therapy with or without
HMGCoA reductase inhibitor (statin) according to 2:1 random distri-
bution. The level of blood lipid (including triglyceride, total choles-
terol, LDL-c, HDL-c), the liver function (including ALT, AST, g-GT and
bilirubin), creatase, renal function and the copy of hepatitis B Virus
were assessed at baseline, and after 1, 3, 6 month of atorvastatin
(20mg/d) treatment. The experiments comply with the current law of
China.
RESULTS A signiﬁcant reduction was revealed in serum triglyceride,
total cholesterol, LDL-c, and signiﬁcant increase in serum HDL-c level
in group with atorvastatin at 1, 3, 6month respectively (all P < 0.05).
There is no difference in ALT, AST, gGT, bilirubin, creatase, and the
copy of hepatitis B Virus in the case group received atorvasta-
tin(20mg/d) at (all P > 0.05).
CONCLUSIONS The use of HMG-CoA reductase inhibitor (statins)
maybe is safety in acute coronary syndrome patients with hepatitis B
Virus and normal liver function.
